SHFM3 Inhibitors
Chemical inhibitors of SHFM3 function through various mechanisms, primarily targeting the proteostasis network within the cell. Proteasome inhibitors such as MG132, Bortezomib, Carfilzomib, Ixazomib, Oprozomib, Marizomib, Delanzomib, MLN2238, Epoxomicin, Lactacystin, and Velcade disrupt the ubiquitin-proteasome system, which is responsible for the degradation of misfolded or damaged proteins. By inhibiting the proteasome, these chemicals lead to an accumulation of proteins within the cell. This accumulation can include regulatory proteins that are crucial for the stability and proper functioning of SHFM3. As these regulatory proteins build up, they can exert inhibitory effects on SHFM3, preventing it from functioning correctly. The inhibition of the proteasome affects the turnover of proteins that modulate the function and stability of SHFM3, thereby leading to its functional inhibition. The precise mechanism of inhibition may involve the disruption of proteolytic pathways that are essential for the activation or repression of SHFM3's activity.
Moreover, a chemical like Auranofin targets the thioredoxin reductase, an enzyme that maintains the cellular redox balance. By inhibiting this enzyme, Auranofin can disrupt the redox state in the cell, which is known to influence the activity of various proteins. This disruption can extend to proteins that directly or indirectly regulate the function of SHFM3, leading to its inhibition. Notably, the action of Auranofin provides an example of how altering a cellular process, in this case, the redox balance, can result in the inhibition of SHFM3 by affecting its regulatory mechanisms. The common theme among these chemical inhibitors is their ability to interfere with cellular systems that, when dysregulated, lead to the inhibition of the SHFM3 protein function, highlighting the interconnected nature of cellular pathways and protein function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can indirectly inhibit SHFM3 by preventing the degradation of regulatory proteins that ensure the stability and proper functioning of SHFM3, thus leading to its functional inhibition due to the accumulation of misfolded or damaged proteins. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib specifically inhibits the 26S proteasome, which may lead to the indirect inhibition of SHFM3 by disrupting the proteolytic degradation of proteins that control its function, resulting in the dysregulation and inhibition of SHFM3 activity. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is a selective proteasome inhibitor that could indirectly inhibit SHFM3 by impairing the degradation of proteins that are involved in the regulation of SHFM3, leading to a potential build-up of regulatory proteins that inhibit SHFM3 function. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib acts on the proteasome, potentially leading to indirect inhibition of SHFM3 by altering the turnover of proteins that modulate the function and stability of SHFM3, thus inhibiting its activity. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is a proteasome inhibitor that can indirectly inhibit SHFM3 by affecting the degradation pathway of proteins that are essential for the proper function of SHFM3, resulting in its functional inhibition. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is a proteasome inhibitor that may indirectly inhibit SHFM3 by preventing the proteolytic breakdown of proteins that regulate the activity of SHFM3, leading to its functional inhibition. | ||||||
Auranofin | 34031-32-8 | sc-202476 sc-202476A sc-202476B | 25 mg 100 mg 2 g | $153.00 $214.00 $4000.00 | 39 | |
Auranofin inhibits the thioredoxin reductase, which can indirectly lead to the inhibition of SHFM3 by disrupting the cellular redox state, which may influence the activity of proteins regulating SHFM3. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor that may indirectly inhibit SHFM3 by preventing the proteolytic degradation of proteins involved in SHFM3 regulation, thus impeding its functional activity. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a proteasome inhibitor that could indirectly inhibit SHFM3 by altering the degradation of regulatory proteins that control SHFM3 activity, resulting in its functional inhibition. | ||||||